Citation: Wj. Shih et H. Quan, Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies, STAT MED, 18(8), 1999, pp. 961-973
Authors:
Lanza, FL
Rack, MF
Simon, TJ
Quan, H
Bolognese, JA
Hoover, ME
Wilson, FR
Harper, SE
Citation: Fl. Lanza et al., Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen, ALIM PHARM, 13(6), 1999, pp. 761-767
Authors:
Catella-Lawson, F
McAdam, B
Morrison, BW
Kapoor, S
Kujubu, D
Antes, L
Lasseter, KC
Quan, H
Gertz, BJ
Fitzgerald, GA
Citation: F. Catella-lawson et al., Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J PHARM EXP, 289(2), 1999, pp. 735-741
Citation: M. Tamura et al., Utility of silicon tetrafluoride as a catalyst of reactions with xenon difluoride: fluorinations of phenyl alkenes and benzaldehydes, J FLUORINE, 98(2), 1999, pp. 163-166
Authors:
Laine, L
Harper, S
Simon, T
Bath, R
Johanson, J
Schwartz, H
Stern, S
Quan, H
Bolognese, J
Citation: L. Laine et al., A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucose of patients with osteoarthritis, GASTROENTY, 117(4), 1999, pp. 776-783
Authors:
Devereaux, PJ
Ghali, WA
Gibson, NE
Skjodt, NM
Ford, DC
Quan, H
Guyatt, GH
Citation: Pj. Devereaux et al., Physician estimates of perioperative cardiac risk in patients undergoing noncardiac surgery, ARCH IN MED, 159(7), 1999, pp. 713-717